ArticleInternational journal of clinical and experimental medicine2015
Prognostic significance of tissue miR-345 downregulation in non-small cell lung cancer.
Article in International journal of clinical and experimental medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Silencing the expression of lncRNAAnnals of translational medicine · 2022Article
- Molecular Pathology of Lung Cancer.Cold Spring Harbor perspectives in medicine · 2022Review
- Salivary miR-31-5p, miR-345-3p, and miR-424-3p Are Reliable Biomarkers in Patients with Oral Squamous Cell Carcinoma.Pathogens (Basel, Switzerland) · 2022Article
- Emerging Role of miR-345 and Its Effective Delivery as a Potential Therapeutic Candidate in Pancreatic Cancer and Other Cancers.Pharmaceutics · 2021Review
- SARS-CoV-2 may regulate cellular responses through depletion of specific host miRNAs.American journal of physiology. Lung cellular and molecular physiology · 2020Article
- Circulating miR-92b and miR-375 for monitoring the chemoresistance and prognosis of small cell lung cancer.Scientific reports · 2020Article
- MiR-345-5p inhibits tumorigenesis of papillary thyroid carcinoma by targeting SETD7.Archives of medical science : AMS · 2020Article
- Trans-3,5,4´-trimethoxystilbene reduced gefitinib resistance in NSCLCs via suppressing MAPK/Akt/Bcl-2 pathway by upregulation of miR-345 and miR-498.Journal of cellular and molecular medicine · 2019Article
- MicroRNA-345 inhibits metastasis and epithelial-mesenchymal transition of gastric cancer by targeting FOXQ1.Oncology reports · 2017Article
- Epigenetic inactivation of tumour suppressor coding and non-coding genes in human cancer: an update.Open biology · 2017Review
- MicroRNA-345 inhibits hepatocellular carcinoma metastasis by inhibiting YAP1.Oncology reports · 2017Article
- Estimating survival time of patients with glioblastoma multiforme and characterization of the identified microRNA signatures.BMC genomics · 2016Article
- Diagnostic and prognostic value of plasma microRNA-195 in patients with non-small cell lung cancer.World journal of surgical oncology · 2016Article
- An miRNA Signature Predicts Grading of Pancreatic Neuroendocrine Neoplasms.Cancer genomics & proteomicsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMiRNAs might function as oncogenes or tumor suppressor genes in the tumorigenesis process. Dysregulation of miR-345 is a frequent event in many types of human cancers. However, the tissue miR-345 expression level in non-small cell lung cancer (NSCLC) and its potential clinical significance remains unknown. MATERIALS AND
methodsReal-time PCR was conducted to evaluate the expression level of miR-345 in NSCLC tissues as well as cell lines. Then the association between tissue miR-345 expression level and clinical outcome was investigated.
resultsThe expression level of miR-345 was significantly decreased in NSCLC tissues and cell lines compared with the controls (P<0.05; P<0.01). Tissue miR-345 expression level was associated with various clinicopathological parameters including LN metastasis (P=0.012), distant metastasis (P=0.007), TNM stage (P=0.008) and grade (P=0.030). In addition, the NSCLC patients in thelow tissue miR-345 expression group had significantly shorter 5-year overall survival time than those in the high tissue miR-345expression group (P=0.016). Multivariate analysis showed that tissue miR-345 was an independent risk factor for NSCLC (HR=3.921, 95% CI: 2.285-10.540; P=0.008).
conclusionsThe expression level of miR-345 was reduced in NSCLC tissues and cell lines. Low tissue miR-345 expression was associated with progression and poor prognosis of NSCLC, indicating that tissue miR-345 may serve as a novel prognostic marker in NSCLC.
Indexed as
Identifiers
26885027PMC4723872What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.